Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway

被引:14
|
作者
Nyga, Mari [1 ,11 ]
Engesaeter, Birgit [1 ]
Castle, Philip E. [2 ,3 ]
Berland, Jannicke Mohr [4 ]
Eide, Maj Liv [5 ]
Iversen, Ole Erik [6 ,7 ]
Jonassen, Christine Monceyron [8 ]
Christiansen, Irene Kraus [9 ]
Vintermyr, Olav Karsten [7 ,10 ]
Trope, Ameli [1 ]
机构
[1] Canc Registry Norway, Oslo, Norway
[2] NCI, Div Canc Prevent, NIH, Rockville, MD USA
[3] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[4] Stavanger Univ Hosp, Stavanger, Rogaland, Norway
[5] Trondheim Reg & Univ Hosp, Trondheim, Norway
[6] Univ Bergen, Inst Clin Sci, Bergen, Norway
[7] Haukeland Hosp, Bergen, Norway
[8] Ostfold Hosp Trust, Ctr Lab Med, Gralum, Norway
[9] Akershus Univ Hosp, Lorenskog, Norway
[10] Univ Bergen, Gades Lab Pathol, Bergen, Norway
[11] Canc Reg istry Norway, Res Dept, Postbox Majorstuen 5313, N-0304 Oslo, Norway
关键词
INTRAEPITHELIAL NEOPLASIA; FOLLOW-UP; CYTOLOGY; RISK; PREVENTION; TRIAGE;
D O I
10.1158/1055-9965.EPI-22-0340
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cervical cancer screening programs are facing a programmatic shift where screening protocol based on human papillomavirus testing (HPV-Screening protocol) is replacing the liquid-based cytology (LBC-Screening protocol). For safe technol-ogy transfer within the nationwide screening programme in Nor-way, HPV-Screening protocol was implemented randomized to compare the real-world effectiveness of HPV-Screening protocol and LBC-Screening protocol at the first screening round. Methods: Among 302,295 women ages 34 to 69 years scheduled to attend screening from February 2015 to June 2017, 157,447 attended. A total of 77,207 were randomly allocated to the HPV-Screening protocol and 80,240 were allocated to the LBC-Screening protocol. All women were followed up for 18 months. Results: The HPV-Screening protocol resulted in a relative increase of 60% in the detection of cervical intraepithelial neoplasia (CIN) grade 2 or worse [risk ratio (RR) = 1.6, 95% confidence interval (CI) = 1.5-1.7], 40% in CIN grade 3 or worse (RR = 1.4, 95% CI = 1.3-1.6), 40% in cancer (RR = 1.4, 95% CI = 1.0-2.1), and 60% in colposcopy referrals (RR = 1.6, 95% CI = 1.5-1.6) compared with LBC-Screening. The perfor-mance of both protocols was age dependent, being more effective in women ages under 50 years. Conclusions: The HPV-Screening protocol was well accepted by women in Norway and detected more CIN2, CIN3, and cancers compared with the LBC-Screening protocol.Impact: A randomized implementation of the HPV-Screening protocol with real-world assessment enabled a gradual, quality assured, and safe technology transition. HPV-based screening protocol may further be improved by using HPV genotyping and age-specific referral algorithms.
引用
收藏
页码:1812 / 1822
页数:11
相关论文
共 50 条
  • [31] A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening
    Patanwala, Insiyyah Y.
    Bauer, Heidi M.
    Miyamoto, Justin
    Park, Ina U.
    Huchko, Megan J.
    Smith-McCune, Karen K.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (05) : 343 - 353
  • [32] Cervical screening with human papillomavirus primary testing: the way forward
    Palmer, T. J.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (03) : 583 - 583
  • [33] Quality assurance in human papillomavirus testing for primary cervical screening
    Cuschieri, Kate
    Fellner, Maria Dolores
    Arroyo Muehr, Laila Sara
    Padalko, Elizaveta
    Correa, Rita Mariel
    Dillner, Joakim
    Gultekin, Murat
    Picconi, Maria Alejandra
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (05) : 802 - 811
  • [34] Primary Human Papillomavirus Screening: Women's Perceptions of New Cervical Cancer Screening Recommendations
    Cannizzaro, Nancy T.
    Mittman, Brian S.
    Hahn, Erin E.
    Ngo-Metzger, Quyen
    Gould, Michael K.
    Hsu, Chunyi
    Shen, Ernest
    Tewari, Devansu
    Chao, Chun R.
    JOURNAL OF WOMENS HEALTH, 2024, 33 (12) : 1614 - 1624
  • [35] The psychosocial impact of human papillomavirus testing in primary cervical screening - a study within a randomized trial
    Kitchener, H. C.
    Fletcher, I.
    Robert, C.
    Wheeler, P.
    Almonte, M.
    Maguire, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (04) : 743 - 748
  • [36] Should screening for cervical cancer go to primary human papillomavirus testing and eliminate cytology?
    Swid, Mohammed Amer
    Monaco, Sara E.
    MODERN PATHOLOGY, 2022, 35 (07) : 858 - 864
  • [37] Preferences for Human Papillomavirus Testing with Routine Cervical Cancer Screening in Diverse Older Women
    Alison J. Huang
    Eliseo J. Pérez-Stable
    Sue E. Kim
    Sabrina T. Wong
    Celia P. Kaplan
    Judith M. E. Walsh
    A. Yuri Iwaoka-Scott
    George F. Sawaya
    Journal of General Internal Medicine, 2008, 23
  • [38] Preferences for human papillomavirus testing with routine cervical cancer screening in diverse older women
    Huang, Alison J.
    Perez-Stable, Eliseo J.
    Kim, Sue E.
    Wong, Sabrina T.
    Kaplan, Celia P.
    Walsh, Judith M. E.
    Iwaoka-Scott, A. Yuri
    Sawaya, George F.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (09) : 1324 - 1329
  • [39] Human papillomavirus testing in primary screening for cervical cancer of human immunodeficiency virus-infected women, 1990-1998
    Petry, KU
    Böhmer, G
    Iftner, T
    Flemming, P
    Stoll, M
    Schmidt, RE
    GYNECOLOGIC ONCOLOGY, 1999, 75 (03) : 427 - 431
  • [40] Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more
    Goldie, SJ
    Kim, JJ
    Wright, TC
    OBSTETRICS AND GYNECOLOGY, 2004, 103 (04): : 619 - 631